Qiagen NV (QGEN) Receives Average Recommendation of “Buy” from Analysts

Qiagen NV (NYSE:QGEN) has earned an average recommendation of “Buy” from the thirteen analysts that are covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $41.00.

QGEN has been the subject of a number of research analyst reports. Deutsche Bank reiterated a “buy” rating on shares of Qiagen in a research report on Wednesday, May 8th. Goldman Sachs Group reiterated a “buy” rating on shares of Qiagen in a research report on Tuesday, May 7th. Zacks Investment Research upgraded shares of Qiagen from a “sell” rating to a “buy” rating and set a $45.00 price objective for the company in a research report on Tuesday, April 16th. UBS Group initiated coverage on shares of Qiagen in a research report on Friday, March 15th. They set a “neutral” rating and a $42.00 price objective for the company. Finally, Wolfe Research initiated coverage on shares of Qiagen in a research report on Thursday, May 30th. They set a “peer perform” rating for the company.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Massachusetts Financial Services Co. MA increased its position in Qiagen by 4.0% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 12,615,185 shares of the company’s stock valued at $434,593,000 after acquiring an additional 481,606 shares during the period. Wellington Management Group LLP increased its position in Qiagen by 16.1% in the 1st quarter. Wellington Management Group LLP now owns 11,556,255 shares of the company’s stock valued at $468,969,000 after acquiring an additional 1,598,649 shares during the period. BlackRock Inc. increased its position in Qiagen by 5.4% in the 4th quarter. BlackRock Inc. now owns 6,607,877 shares of the company’s stock valued at $227,642,000 after acquiring an additional 336,763 shares during the period. Hardman Johnston Global Advisors LLC increased its position in Qiagen by 5.5% in the 4th quarter. Hardman Johnston Global Advisors LLC now owns 4,407,084 shares of the company’s stock valued at $151,824,000 after acquiring an additional 229,824 shares during the period. Finally, First Trust Advisors LP increased its position in Qiagen by 6.8% in the 1st quarter. First Trust Advisors LP now owns 2,685,140 shares of the company’s stock valued at $109,231,000 after acquiring an additional 169,926 shares during the period. Hedge funds and other institutional investors own 63.22% of the company’s stock.

Shares of Qiagen stock opened at $38.92 on Friday. Qiagen has a 1-year low of $32.33 and a 1-year high of $41.55. The company has a quick ratio of 1.52, a current ratio of 1.69 and a debt-to-equity ratio of 0.54. The company has a market cap of $8.75 billion, a PE ratio of 29.04, a PEG ratio of 2.33 and a beta of 0.84.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Monday, May 6th. The company reported $0.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.26 by $0.01. The company had revenue of $348.70 million during the quarter, compared to the consensus estimate of $351.68 million. Qiagen had a net margin of 12.45% and a return on equity of 12.22%. The firm’s quarterly revenue was up 1.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.26 EPS. On average, research analysts forecast that Qiagen will post 1.43 earnings per share for the current year.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Read More: What are Institutional Investors?

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.